Wednesday, March 01, 2006

Aromasin (exemestane) Improves Breast Cancer Outcomes Without Compromising Quality of Life, February 28, 2006
Breast cancer patients who switched to Aromasin® (exemestane) after 2-3 years of Nolvadex® (tamoxifen) reported a similar quality of life to patients who continued on Nolvadex. These results were published in the Journal of Clinical Oncology. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */